Pre-made Vapaliximab benchmark antibody (Whole mAb, anti-AOC3 therapeutic antibody, Anti-HPAO/SSAO/VAP-1/VAP1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-AOC3 therapeutic antibody (Pre-made Vapaliximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vapaliximab is a chimeric monoclonal antibody[1] and an experimental immunosuppressive drug.[citation needed] Development was discontinued by 212.[2]
| Products Name (INN Index) | Pre-Made Vapaliximab Biosimilar, Whole Mab, Anti-Aoc3 Antibody: Anti-HPAO/SSAO/VAP-1/VAP1 therapeutic antibody |
|---|---|
| INN Name | vapaliximab |
| Target | AOC3 |
| Format | Whole mAb |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 – kappa |
| VD LC | IgG2 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | AOC3 |
| Package |
